1-3 of 3
Mark R. Lipstein
Close
Sort by
Journal Articles

Silencing Oncogene Translation Using Pateamine a Analogues As a Novel Therapeutic Strategy for c-Myc Driven Lymphoma

Yu Ri Kim, MD, Ipsita Pal, PhD, Mark R Lipstein, PhD, Mingzhao Zhu, Hull Kenneth, Daniel Romo, Owen A. O'Connor, MD, PhD, Changchun Deng, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4111.
https://doi.org/10.1182/blood.V130.Suppl_1.4111.4111
Published: 2017
Journal Articles

Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas

Ipsita Pal, PhD, Yu Ri Kim, MD, Luigi Scotto, PhD, Mark R Lipstein, PhD, Abdullah Mahmood Ali, PhD, Siddhartha Mukherjee, MD PhD, Susan E. Bates, MDPhD, Owen A. O'Connor, MD, PhD, Changchun Deng, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2809.
https://doi.org/10.1182/blood.V130.Suppl_1.2809.2809
Published: 2017
Journal Articles

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

Clinical Trials & Observations
Changchun Deng, Mark R. Lipstein, Luigi Scotto, Xavier O. Jirau Serrano, Michael A. Mangone, Shirong Li, Jeremie Vendome, Yun Hao, Xiaoming Xu, Shi-Xian Deng, Ronald B. Realubit, Nicholas P. Tatonetti, Charles Karan, Suzanne Lentzsch, David A. Fruman, Barry Honig, Donald W. Landry, Owen A. O’Connor
Journal: Blood
Blood (2017) 129 (1): 88–99.
https://doi.org/10.1182/blood-2016-08-731240
Published: 2017
Includes: Supplemental data